Belimumab has been studied in a limited number of SLE patients with renal syringe are provided at the end of the package leaflet (see Step-by-step. Learn about BENLYSTA (belimumab), an FDA-approved prescription infusion or self-injectable lupus medication to help treat your Request your FREE Info Kit. Keep in the original package until time of use to protect from light. Insert the entire Needle into the pinched area of the skin at a slight degree angle using a.
|Published (Last):||26 November 2014|
|PDF File Size:||18.79 Mb|
|ePub File Size:||5.34 Mb|
|Price:||Free* [*Free Regsitration Required]|
Reductions in naive and the SLE B-cell subset were observed as early as week 8 and were sustained to week Depression, psychiatric event, suicidal ideation. Belimumab has not been studied in combination with other biologic therapies including B-cell targeted therapies such as ocrelizumab. The mechanism of action of belimumab could increase the risk for the development of malignancies. Administration of IV infusion: The clinical relevance of these effects on B cells has not been established.
Continue to hold the auto-injector down until you see that the purple indicator has stopped moving. Preparation of Solutions BENLYSTA is provided as a lyophilized powder in a single-use vial for intravenous infusion only and should be reconstituted and diluted by a healthcare professional using aseptic technique as follows: Live virus vaccines may induce the illness they are intended to prevent and are generally contraindicated for use during immunosuppressive treatment.
Use belimumab therapy cautiously in patients with a history of depression or other psychiatric disorders. Small air bubbles, however, are expected and acceptable.
Clinical studies did not include sufficient numbers of patients more than 65 years of age to determine whether they respond differently than younger patients; most patients in clinical trials were adults 45 years of age and younger. Tumor Necrosis Factor modifiers: Consider administering premedication for prophylaxis against infusion reactions and hypersensitivity reactions. Reconstitution is typically complete within 10 to 15 minutes after the sterile water has been added, but it may take up to 30 minutes.
The needle will automatically rise up into the needle guard. Belimumab has not been studied in combination with other biologic therapies including B-cell targeted therapies such as ofatumumab.
Your Name Your name is required. It is unknown if treatment with belimumab is associated with increased risk for these events.
Adverse events associated with the infusion may also occur. Dispose of any used pre-filled syringes or auto-injectors immediately after use.
Reconstitute the mg vial with 1. Monitor an infant of a belimumab-treated mother for B-cell reduction and other immune dysfunction after birth. The stream of sterile water should be directed toward the side of the vial to minimize foaming. Small air bubbles, however, are packags and acceptable. Do not inject gelimumab 2 inches of the umbilicus.
Belimumab has not been studied in combination with other biologic therapies including tumor necrosis factor modifiers TNF blockers.
Only healthcare providers prepared to manage anaphylaxis should administer belimumab by infusion. Potential concerns with use of these drugs together include an increased susceptibility to immunosuppression and serious infections, some of which might be fatal. If transitioning from intravenous to subcutaneous therapy, administer the first subcutaneous dose 1 to 4 weeks after the last intravenous dose. Therefore, belimumab use is not recommended in combination with intravenous cyclophosphamide.
The manufacturer recommends using belimumab with caution in geriatric patients. The injection may take up to 15 seconds to complete.
gelimumab BENLYSTA is a sterile, preservative-free lyophilized powder for reconstitution, dilution, and intravenous infusion provided in single-use glass vials with a latex-free rubber stopper and a flip-off seal.
It is important to note that hypersensitivity reactions may present as infusion reactions. Patients may use the prefilled syringe or auto-injector after proper training.
Administration of belimumab requires an experienced clinician prepared to manage anaphylaxis and infusion-related reactions. Belimumab should be clear to opalescent and colorless to pale yellow.
If not used immediately, protect the reconstitued vial from direct sunlight and refrigerate at 2 to 8 degrees C 36 to 46 degrees F. Therefore, belimumab use is not recommended in combination with TNF ;ackage. Dilute the reconstituted product to mL in 0. Receipt of belimumab also led to reductions in IgG and anti-dsDNA and to increases in complement C3 and C4 as early as week 8 and were sustained through week No data are available on the secondary transmission of infection from persons receiving live vaccines.